Dual PDE3/4 and PDE4 inhibitors: Novel treatments for COPD and other inflammatory airway diseases

Basic and Clinical Pharmacology and Toxicology

Volumn 114, Issue 5, 2014, Pages 365-376

  Abbott Banner, Katharine H ^a   Page, Clive P ^b  

^a Verona Pharma Plc   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEN(Z)AFENTRINE; BENZAFENTRINE; BENZOIC ACID DERIVATIVE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CILOMILAST; GSK 256066; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 13; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; MUSCARINIC RECEPTOR BLOCKING AGENT; N (3,5 DICHLORO 4 PYRIDYL) [1 (4 FLUOROBENZYL) 5 HYDROXY 3 INDOLYL]GLYOXYLIC ACID AMIDE; PHOSPHODIESTERASE III; PHOSPHODIESTERASE III INHIBITOR; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; PLACEBO; PUMAFENTRINE; ROFLUMILAST; ROLIPRAM; RPL 554; SALBUTAMOL; SALMETEROL; SDZ ISQ 844; TOFIMILAST; TOLAFENTRINE; TUMOR NECROSIS FACTOR ALPHA; UK 500 001; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZARDAVERINE; ANTIINFLAMMATORY AGENT; BRONCHODILATING AGENT;

AIRWAY REMODELING; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; BLOOD VESSEL INJURY; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HUMAN; LUNG FIBROSIS; MUCOCILIARY CLEARANCE; MUCUS SECRETION; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT INFLAMMATION; SYSTEMIC CIRCULATION; TREATMENT OUTCOME; ANIMAL; DRUG EFFECTS; ENZYMOLOGY; INFLAMMATION; METABOLISM; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY TRACT DISEASES;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BRONCHODILATOR AGENTS; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 3; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; HUMANS; INFLAMMATION; PHOSPHODIESTERASE 3 INHIBITORS; PHOSPHODIESTERASE 4 INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY TRACT DISEASES;

EID: 84897959610     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/bcpt.12209     Document Type: Article

References (134)

1. www.who.int/respiratory/copd/en
2. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of COPD, 2011 Update. www.goldcopd.org GOLD guidelines.
3. Mahler DA, Wire P, Horstman D, Chang CN, Yates J, Fischer T, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;166:1084-91.
4. Hogg JC, Chu FS, Tan WC, Sin DD, Patel SA, Pare PD, et al. Survival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airway pathology. Am J Respir Crit Care Med 2007;176:454-9.
5. Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. Lancet 2007;370:786-96.
6. Yawn BP, Li Y, Tian H, Zhang J, Arcona S, Kahler KH. Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis. Int J Chron Obstruct Pulmon Dis 2013;8:295-304.
7. Saetta M, Di SA, Maestrelli P, Ferraresso A, Drigo R, Potena A, et al. Activated T-lymphocytes and macrophages in bronchial mucosa of subjects with chronic bronchitis. Am Rev Respir Dis 1993;147:301-6.
8. Riise GC, Ahlstedt S, Larsson S, Enander I, Jones I, Larsson P, et al. Bronchial inflammation in chronic bronchitis assessed by measurement of cell products in bronchial lavage fluid. Thorax 1995;50:360-5.
9. Vassallo R, Kroening PR, Parambil J, Kita H. Nicotine and oxidative cigarette smoke constituents induce immune-modulatory and pro-inflammatory dendritic cell responses. Mol Immunol 2008;45:3321-9.
10. Barnes PJ. New concepts in chronic obstructive pulmonary disease. Annu Rev Med 2003;54:113-29.
11. Drost EM, Skwarski KM, Sauleda J, Soler N, Roca J, Agusti A, et al. Oxidative stress and airway inflammation in severe exacerbations of COPD. Thorax 2005;60:293-300.
12. Qiu Y, Zhu J, Bandi V, Atmar RL, Hattotuwa K, Guntupalli KK, et al. Biopsy neutrophilia, neutrophil chemokine and receptor gene expression in severe exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003;168:968-75.
13. Saetta M, Di SA, Maestrelli P, Turato G, Ruggieri MP, Roggeri A, et al. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med 1994;150(6 Pt 1):1646-52.
14. Celli BR, Thomas NR, Andersson JA, Ferguson GT, Jenkins CR, Jones PW, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary diseases: results from the TORCH study. Am J Respir Crit Care Med 2008;178:332-8.
15. Liu S, Veilleux A, Zhang L, Young A, Kwok E, Laliberté F, et al. Dynamic activation of cystic fibrosis transmembrane conductance regulator by type 3 and type 4D phosphodiesterase inhibitors. J Pharmacol Exp Ther 2005;314:846-54.
16. Bodas M, Min T, Mazur S, Vij N. Critical modifier role of membrane-cystic fibrosis transmembrane conductance regulator-dependent ceramide signaling in lung injury and emphysema. J Immunol 2011;186:602-13.
17. Beavo JA, Brunton LL. Cyclic nucleotide research - still expanding after half a century. Nat Rev Mol Cell Biol 2002;3:710-8.
18. Conti M, Richter W, Mehats C, Livera G, Park J-Y, Jin C. Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. J Biol Chem 2003;278:5493.
19. Bingham J, Sudarsanam S, Srinivasan S. Profiling human phosphodiesterase genes and splice isoforms. Biochem and Biophys Res Comm 2006;350:25-32.
20. Zhang KY, Ibrahim PN, Gillette S, Bollag G. Phosphodiesterase 4 as a potential drug target. Expert Opin Ther Targets 2005;9:1283-305.
21. Barber R, Baillie GS, Bergmann R, Shepherd MC, Sepper R, Houslay MD, et al. Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers. Am J Physiol Lung Cell Mol Physiol 2004;287:L332-43.
22. Baroja ML, Cieslinski LB, Torphy TJ, Wange RL, Madrenas J, Gantner F, et al. Specific CD3e association of a phosphodiesterase 4B isoform determines its selective tyrosine phosphorylation after CD3 ligation. J Immunol 1999;162:2016-23.
23. Billington CK, LeJeune IR, Young KW, Hall IP. A major functional role for phosphodiesterase 4D5 in human airway smooth muscle cells. Am J Respir Cell Mol Biol 2008;38:1-7.
24. (2+) responses in endothelial cells. Br J Pharmacol 2008;154:82-92.
25. Fuhrmann M, Jahn HU, Seybold J, Neurohr C, Barnes PJ, Hippenstiel S, et al. Identification and function of cyclic nucleotide phosphodiesterase isoenzymes in airway epithelial cells. Am J Respir Cell Mol Biol 1999;20:292-302.
26. Gantner F, Gotz C, Gekeler V, Schudt C, Wendel A, Hatzelmann A. Phosphodiesterase profile of human B lymphocytes from normal and atopic donors and the effects of PDE inhibition on B cell proliferation. Br J Pharmacol 1998;123:1031-8.
27. Giembycz MA, Corrigan CJ, Seybold J, Newton R, Barnes PJ. Identification of cyclic AMP phosphodiesterases 3, 4 and 7 in human CD4+ and CD8+ T-lymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2. Br J Pharmacol 1996;118:1945-58.
28. Ito M, Nishikawa M, Fujioka M, Miyahara M, Isaka N, Shiku H, et al. Characterization of the isoenzymes of cyclic nucleotide phosphodiesterase in human platelets and the effects of E4021. Cell Signal 1996;8:575-81.
29. Landells LJ, Szilagy CM, Jones NA, Banner KH, Allen JM, Doherty A, et al. Identification and quantification of phosphodiesterase 4 subtypes in CD4 and CD8 lymphocytes from healthy and asthmatic subjects. Br J Pharmacol 2001;133:722-9.
30. LeJeune IR, Shepherd M, Van Heeke G, Houslay MD, Hall IP. Cyclic AMP-dependent transcriptional up-regulation of phosphodiesterase 4D5 in human airway smooth muscle cells. J Biol Chem 2002;277:35980-53989.
31. Millen J, MacLean MR, Houslay M. Hypoxia-induced remodelling of PDE4 isoform expression and cAMP handling in human pulmonary artery smooth muscle cells. Eur J Cell Biol 2006;85:679-91.
32. Netherton SJ, Sutton JA, Wilson LS, Carter RL, Maurice DH. Both protein kinase A and exchange protein activated by cAMP coordinate adhesion of human vascular endothelial cells. Circ Res 2007;101:768-76.
33. Netherton SJ, Maurice DH. Vascular endothelial cell cyclic nucleotide phosphodiesterases and regulated cell migration: implications in angiogenesis. Mol Pharmacol 2005;67:263-72.
34. Peachell PT, Undem BJ, Schleimer RP, MacGlashan D, Lichtenstein L, Cieslinski LB, et al. Preliminary identification and role of phosphodiesterase isozymes in human basophils. J Immunol 1992;148:2503-10.
35. Peter D, Jin SL, Conti M, Hatzelmann A, Zitt C. Differential expression and function of phosphodiesterase 4 (PDE4) subtypes in human primary CD4+ T cells: predominant role of PDE4D. J Immunol 2007;178:4820-31.
36. Pryzwansky KB, Madden VJ. Type 4A cAMP-specific phosphodiesterase is stored in granules of human neutrophils and eosinophils. Cell Tissue Res 2003;312:301-11.
37. Tilley DG, Maurice DH. Vascular smooth muscle cell phenotype-dependent phosphodiesterase 4D short form expression: role of differential histone acetylation on cAMP-regulated function. Mol Pharmacol 2005;68:596-605.
38. Wang P, Wu P, Ohleth K, Egan R, Billah M. Phosphodiesterase 4B2 is the predominant phosphodiesterase species and undergoes differential regulation of gene expression in human monocytes and neutrophils. Mol Pharmacol 1999;56:170-4.
39. Wright LC, Seybold J, Robichaud A, Adcock I, Barnes P. Phosphodiesterase expression in human epithelial cells. Am J Physiol 1998;275:L694-700.
40. Shakur Y, Holst LS, Landstrom TR, Movsesian M, Degerman E, Manganiello V. Regulation and function of the cyclic nucleotide phosphodiesterase (PDE3) gene family. Prog Nucleic Acid Res Mol Biol 2001;66:241-77.
41. Edmondson SD, Mastracchio A, He J, Chung CC, Forrest MJ, Hofsess S, et al. Benzyl vinylogous amide substituted aryldihydropyridazinones and aryldimethylpyrazolones as potent and selective PDE3B inhibitors. Bioorg Med Chem Lett 2003;13:3983-7.
42. Sudo T, Tachibana K, Toga K, Tochizawa S, Inoue Y, Kimura Y, et al. Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity. Biochem Pharmacol 2000;59:347-56.
43. Banner KH, Moriggi E, Da RB, Schioppacassi G, Semeraro C, Page CP. The effect of selective phosphodiesterase 3 and 4 isoenzyme inhibitors and established anti-asthma drugs on inflammatory cell activation. Br J Pharmacol 1996;119:1255-61.
44. Hatzelmann A, Schudt C. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 2001;297:267-79.
45. Trevethick M, Banner KH, Ballard S, Barnard A, Lewis A, Browne J et al. UK-500, 001, a potent selective inhibitor of phosphodiesterase type 4 (PDE4) designed for inhaled delivery, inhibits TNF-a, MIP-1b and LTB4 release from native human blood cells. ATS. 2007a: abst. A116.
46. Jones NA, Boswell-Smith V, Lever R, Page CP. The effect of selective phosphodiesterase isoenzyme inhibition on neutrophil function in vitro. Pulm Pharmacol Ther 2005;18:93-101.
47. Schudt C, Tenor H, Loos U, Mallmann P, Szamel M, Resch K. Effects of selective PDE inhibitors on activation of human macrophages and lymphocytes. Eur Respir J 1993;6(Suppl 17):367S.
48. Gantner F, Schudt C, Wendel A, Hatzelmann A. Characterization of the phosphodiesterase (PDE) pattern of in vitro-generated human dendritic cells (DC) and the influence of PDE inhibitors on DC function. Pulm Pharmacol Ther 1999;12:377-86.
49. Blease K, Burke-Gaffney A, Hellewell PG. Modulation of cell adhesion molecule expression and function on human lung microvascular endothelial cells by inhibition of phosphodiesterases 3 and 4. Br J Pharmacol 1998;124:229-37.
50. Milara J, Navarro A, Almudever P, Lluch J, Morcillo EJ, Cortijo J. Oxidative stress-induced glucocorticoid resistance is prevented by dual PDE3/4 inhibition in human alveolar macrophages. Clin Exp Allergy 2011;41:535-46.
51. Myou S, Fujimura M, Kamio Y, Hirose T, Kita T, Tachibana H, et al. Bronchodilator effects of intravenous olprinone, a phosphodiesterase 3 inhibitor, with and without aminophylline in asthmatic patients. Br J Clin Pharmacol 2003;55:341-6.
52. Schmidt DT, Watson N, Dent G, Rühlmann E, Branscheid D, Magnussen H, et al. The effect of selective and non-selective phosphodiesterase inhibitors on allergen- and leukotriene C(4)-induced contractions in passively sensitized human airways. Br J Pharmacol 2000;131:1607-18.
53. Challiss RA, Adams D, Mistry R, Nicholson CD. Modulation of spasmogen-stimulated Ins(1, 4, 5)P3 generation and functional responses by selective inhibitors of types 3 and 4 phosphodiesterase in airways smooth muscle. Br J Pharmacol 1998;124:47-54.
54. Rabe KF, Tenor H, Dent G, Schudt C, Liebig S, Magnussen H. Phosphodiesterase isoenzymes modulating inherent tone in human airways: identification and characterization. Am J Physiol 1993;264:L458-64.
55. Naline E, Qian Y, Advenier C, Raeburn D, Karlsson JA. Effects of RP 73401, a novel, potent and selective phosphodiesterase type 4 inhibitor, on contractility of human, isolated bronchial muscle. Br J Pharmacol 1996;118:1939-44.
56. Méhats C, Jin SL, Wahlstrom J, Law E, Umetsu DT, Conti M. PDE4D plays a critical role in the control of airway smooth muscle contraction. FASEB J 2003;17:1831-41.
57. Hirota K, Yoshioka H, Kabara S, Kudo T, Ishihara H, Matsuki A. A comparison of the relaxant effects of olprinone and aminophylline on methacholine-induced bronchoconstriction in dogs. Anesth Analg 2001;93:230-3.
58. Yick CY, Zwinderman AH, Kunst PW, Grünberg K, Mauad T, Dijkhuis A, et al. Transcriptome sequencing (RNA-Seq) of human endobronchial biopsies: asthma versus controls. Eur Respir J 2013;42:662-70.
59. Berends C, Dijkhuizen B, de Monchy JG, Dubois AE, Gerritsen J, Kauffman HF. Inhibition of PAF-induced expression of CD11b and shedding of L-selectin on human neutrophils by the type 4 selective PDE inhibitor, rolipram. Eur Respir J 1997;10:1000-7.
60. Derian CK, Santulli RJ, Rao PE, Solomon HF, Barrett JA. Inhibition of chemotactic peptide-induced neutrophil adhesion to vascular endothelium by cAMP modulators. J Immunol 1995;154:308-17.
61. Tenor H, Hatzelmann A, Church MK, Schudt C, Shute JK. Effects of theophylline and rolipram on leukotriene C4 (LTC4) synthesis and chemotaxis of human eosinophils from normal and atopic subjects. Br J Pharmacol 1996;118:1727-35.
62. Tenor H, Hatzelmann A, Kupferschmidt R, Stanciu L, Djukanoviv R, Schudt C, et al. Cyclic nucleotide phosphodiesterases from purified human CD4+ and CD8+ T lymphocytes. Clin Exp Allergy 1995;25:625-63.
63. Manning CD, Burman M, Christensen SB, Cieslinski LB, Essayan DM, Grous M, et al. Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B. Br J Pharmacol 1999;128:1393.
64. Molnar-Kimber K, Yonno L, Heaslip R, Weichman B. Modulation of TNF alpha and IL-1 beta from endotoxin-stimulated monocytes by selective PDE isozyme inhibitors. Agents Actions 1993;39:C77-9.
65. Jin SL, Conti M. Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses. Proc Natl Acad Sci USA 2002;99:7628-33.
66. Heystek HC, Thierry AC, Soulard P, Moulon C. Phosphodiesterase 4 inhibitors reduce human dendritic cell inflammatory cytokine production and Th1-polarizing capacity. Int Immunol 2003;15:827-35.
67. Essayan DM, Kagey-Sobotka A, Lichtenstein LM, Huang SR. Differential regulation of human antigen-specific Th1 and Th2 lymphocyte responses by isozyme selective cyclic nucleotide phosphodiesterase inhibitors. J Pharmacol Exp Ther 1997;282:505-12.
68. Claveau D, Chen SL, O'Keefe S, Styhler A, Liu S, Huang Z, et al. Preferential inhibition of T helper 1, but not T helper 2, cytokines in vitro by L-826, 141 [4-[2-(3, 4-Bisdifluromethoxyphenyl)-2-[4-(1, 1, 1, 3, 3, 3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]3-methylpyridine-1-oxide], a potent and selective phosphodiesterase 4 inhibitor. J Pharmacol Exp Ther 2004;310:752-60.
69. Haddad JJ, Land SC, Tarnow-Mordi WO, Zembala M, Kowalczyk D, Lauterbach R. Immunopharmacological potential of selective phosphodiesterase inhibition. I. Differential regulation of lipopolysaccharide-mediated proinflammatory cytokine (interleukin-6 and tumor necrosis factor-alpha) biosynthesis in alveolar epithelial cells. J Pharmacol Exp Ther 2002;300:559-66.
70. Mata M, Martinez I, Melero JA, Tenor H, Cortijo J. Roflumilast inhibits respiratory syncytial virus infection in human differentiated bronchial epithelial cells. PLoS ONE 2013;8:e69670.
71. Suttorp N, Weber U, Welsch T, Schudt C. Role of phosphodiesterases in the regulation of endothelial permeability in vitro. J Clin Invest 1993;91:1421-8.
72. Leclerc O, Lagente V, Planquois J-M, Berthelier C, Artola M, Eichholtz T, et al. Involvement of MMP-12 and phosphodiesterase type 4 in cigarette smoke-induced inflammation in mice. Eur Respir J 2006;27:1102-9.
73. Martorana PA, Beume R, Lucattelli M, Wollin L, Lungarella G. Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke. Am J Respir Crit Care Med 2005;172:848-53.
74. Mori H, Nose T, Ishitani K, Kasagi S, Souma S, Akiyoshi T, et al. Phosphodiesterase 4 inhibitor GPD-1116 markedly attenuates the development of cigarette smoke-induced emphysema in senescence-accelerated mice P1 strain. Am J Physiol Lung Cell Mol Physiol 2008;294:L196-204.
75. Lagente V, Martin-Chouly C, Boichot E, Martins MA, Silva PM. Selective PDE4 inhibitors as potent anti-inflammatory drugs for the treatment of airway diseases. Mem Inst Oswaldo Cruz 2005;100(Suppl 1):131-6.
76. Kuss H, Hoefgen N, Johanssen S, Kronbach T, Rundfeld C. In vivo efficacy in airway disease models of N-(3, 5-Dichloro-pyrid-4-yl)-[1-(4-flurobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), a selective phoshodiesterase 4 inhibitor for inhaled administration. JPET 2003;307:373-85.
77. Trevethick M, Philip J, Chaffe P, Sladen L, Cooper C, Nagendra R et al. In vivo profile of intratracheally delivered phosphodiesterase type 4 (PDE4) inhibitor UK-500, 001-Inhibits bronchoconstriction and inflammation. ATS; 2007b: Aabst. A927.
78. Horikoshi S, Imai T, Idaira K, Adachi M, Okamoto M. Effects of inhaled SDZ ISQ 844, a cyclic nucleotide phosphodiesterase isoenzyme type III/IV inhibitor, on airway responsiveness in beagles. Arerugi 1994;43:551-6.
79. Ariga M, Neitzert B, Nakae S, Mottin G, Bertrand C, Pruniaux MP, et al. Non-redundant function of phosphodiesterase 4D and 4B in neutrophil recruitment to the site of inflammation. J Immunol 2004;173:7531-8.
80. Sousa LP, Lopes F, Silva DM, Tavares LP, Vieira AT, Rezende BM, et al. PDE4 inhibition drives resolution of neutrophilic inflammation by inducing apoptosis in a PKA-PI3K/Akt-dependent and NF-kappaB-independent manner. J Leukoc Biol 2010;87:895-904.
81. Kelley TJ, al-Nakkash L, Drumm ML. CFTR-mediated chloride permeability is regulated by type III phosphodiesterases in airway epithelial cells. Am J Respir Cell Mol Biol 1995;13:657-64.
82. Cobb BR, Fan L, Kovacs TE, Sorscher EJ, Clancy JP. Adenosine receptors and phosphodiesterase inhibitors stimulate Cl- secretion in Calu-3 cells. Am J Respir Cell Mol Biol 2003;29(3 Pt 1):410-8.
83. Lambert JA, Raju SV, Tang LP, McNicholas CM, Li Y, Courville CW, et al. CFTR Activation by Roflumilast Contributes to Therapeutic Benefit in Chronic Bronchitis. Am J Respir Cell Mol Biol; 2013 [Epub ahead of print].
84. Cervin A, Lindgren S. The effect of selective phosphodiesterase inhibitors on mucociliary activity in the upper and lower airways in vitro. Auris Nasus Larynx 1998;25:269-76.
85. Burgess JK, Oliver BG, Poniris MH, Ge Q, Boustany S, Cox N, et al. A phosphodiesterase 4 inhibitor inhibits matrix protein deposition in airways in vitro. J Allergy Clin Immunol 2006;118:649-57.
86. Dunkern TR, Feurstein D, Rossi GA, Sabatini F, Hatzelmann A. Inhibition of TGF-beta induced lung fibroblast to myofibroblast conversion by phosphodiesterase inhibiting drugs and activators of soluble guanylyl cyclase. Eur J Pharmacol 2007;572:12-22.
87. Martin-Chouly CA, Astier A, Jacob C, Pruniaux MP, Bertrand C, Lagente V. Modulation of matrix metalloproteinase production from human lung fibroblasts by type 4 phosphodiesterase inhibitors. Life Sci 2004;75:823-40.
88. Kohyama T, Liu X, Wen FQ, Wang H, Kim HJ, Takizawa H, et al. PDE4 inhibitors attenuate fibroblast chemotaxis and contraction of native collagen gels. Am J Respir Cell Mol Biol 2002;26:694-701.
89. Calzetta L, Page CP, Spina D, Cazzola M, Rogliani P, Facciolo F, et al. The effect of the mixed phosphodiesterase 3/4 inhibitor RPL554 on human isolated bronchial smooth muscle tone. J Pharmacol Exp Ther 2013;346:414-23.
90. Rabe KF. Roflumilast for the treatment of chronic obstructive pulmonary disease. Expert Rev Respir Med 2010;4:543-55.
91. Calverley PM, Sanchez-Toril F, McIvor A, Teichmann P, Bredenbroeker D, Fabbri LM. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;176:154-61.
92. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ; M2-124 and M2-125 study groups. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009;374:685-94 doi: 10.1016/S0140-6736(09)61255-1. Erratum in: Lancet. 2010 Oct 2;376(9747):1146.
93. Grootendorst DC, Gauw SA, Verhoosel RM, Sterk PJ, Hospers JJ, Bredenbröker D, et al. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax 2007;62:1081-7.
94. Page CP, Spina D. Phosphodiesterase inhibitors in the treatment of inflammatory diseases. Handb Exp Pharmacol 2011;204:391-414.
95. Duplantier AJ, Bachert EL, Cheng JB, Cohan VL, Jenkinson TH, Kraus KG et al. SAR of a series of 5, 6-dihydro-(9H)-pyrazolo[3, 4-c]-1, 2, 4-triazolo[4, 3-alpha]pyridines as potent inhibitors of human eosinophil phosphodiesterase. J Med Chem 2007;50:344-9.
96. Nials AT, Tralau-Stewart CJ, Gascoigne MH, Ball DI, Ranshaw LE, Knowles RG. In vivo characterization of GSK256066, a high-affinity inhaled phosphodiesterase 4 inhibitor. J Pharmacol Exp Ther 2011;337:137-44.
97. Armani E, Amari G, Rizzi A, De FR, Ghidini E, Capaldi C, et al. A novel class of benzoic acid ester derivatives as potent PDE4 inhibitors for inhaled administration in the treatment of respiratory diseases. J Med Chem 2014;57:793-816.
98. Singh D, Petavy F, Macdonald AJ, Lazaar AL, O'Connor BJ. The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma. Respir Res 2010;11:26.
99. Phillips P, Bennetts M, Banner K, Ward J, et al. The inhaled PDE4 inhibitor UK-500, 001 does not significantly attenuate airway responses to allergen and histamine. Eur Respir J 2007;30A:2964.
100. Vestbo J, Tan L, Atkinson G, Ward J; UK-500, 001 Global Study Team. A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD. Eur Respir J 2009;33:1039-44.
101. Lazaar AL, Mistry S, Barrett C, Lulic-Burns Z. The IPC 1019 39 Study team. A 4-week randomized study of the safety and tolerability of the PDE4 inhibitor GSK26066 in COPD patients. Am J Respir Crit Care Med 2010;181:A4444.
102. Van der Mey M, Bommele KM, Boss H, Hatzelmann A, Van Slingerland M, Sterk GJ, et al. Synthesis and structure-activity relationships of cis-tetrahydrophthalazinone/pyridazinone hybrids: a novel series of potent dual PDE3/PDE4 inhibitory agents. J Med Chem 2003;46:2008-16.
103. Rieder F, Siegmund B, Bundschuh DS, Lehr HA, Endres S, Eigler A. The selective phosphodiesterase 4 inhibitor roflumilast and phosphodiesterase 3/4 inhibitor pumafentrine reduce clinical score and TNF expression in experimental colitis in mice. PLoS ONE 2013;8:e56867.
104. Ochiai K, Takita S, Kojima A, Eiraku T, Iwase K, Kishi T, et al. Phosphodiesterase inhibitors Part 5: hybrid PDE3/4 inhibitors as dual bronchorelaxant/anti-inflammatory agents for inhaled administration. Bioorg Med Chem Lett 2013;23:375-81.
105. Schudt C, Winder S, Müller B, Ukena D. Zardaverine as a selective inhibitor of phosphodiesterase isozymes. Biochem Pharmacol 1991;42:153-62.
106. Underwood DC, Kotzer CJ, Bochnowicz S, Osborn RR, Luttmann MA, Hay DW, et al. Comparison of phosphodiesterase III, IV and dual III/IV inhibitors on bronchospasm and pulmonary eosinophil influx in guinea pigs. J Pharmacol Exp Ther 1994;270:250-9.
107. Hoymann HG, Heinrich U, Beume R, Kilian U. Comparative investigation of the effects of zardaverine and theophylline on pulmonary function in rats. Exp Lung Res 1994;20:235-50.
108. Schudt C, Winder S, Eltze M, Kilian U, Beume R. Zardaverine: a cyclic AMP specific PDE III/IV inhibitor. Agents Actions Suppl 1991;34:379-402.
109. Brunnee T, Engelstatter R, Steinijans VW, Kunkel G. Bronchodilatory effect of inhaled zardaverine, a phosphodiesterase III and IV inhibitor, in patients with asthma. Eur Respir J 1992;5:982-5.
110. Ukena D, Rentz K, Reiber C, Sybrecht GW. Effects of the mixed phosphodiesterase III/IV inhibitor, zardaverine, on airway function in patients with chronic airflow obstruction. Respir Med 1995;89:441-4.
111. Hatzelmann A, Engelstaetter R, Morley J, Mazzoni L. Enzymic and functional aspects of dual-selective PDE3/4 inhibitors. In: Schudt C, Dent G, Rabe KF (eds). Phosphodiesterase Inhibitors. Academic Press, London, 1996;147-60.
112. Foster RW, Rakshi K, Carpenter JR, Small RC. Trials of the bronchodilator activity of the isoenzyme-selective phosphodiesterase inhibitor AH 21-132 in healthy volunteers during a methacholine challenge test. Br J Clin Pharmacol 1992;34:527-34.
113. Dony E, Lai YJ, Dumitrascu R, Pullamsetti SS, Savai R, Ghofrani HA, et al. Partial reversal of experimental pulmonary hypertension by phosphodiesterase-3/4 inhibition. Eur Respir J 2008;31:599-610.
114. Giembycz MA. Phosphodiesterase-4: selective and dual-specificity inhibitors for the therapy of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005;2:326-33.
115. Pullamsetti S, Krick S, Yilmaz H, Ghofrani HA, Schudt C, Weissmann N, et al. Inhaled tolafentrine reverses pulmonary vascular remodeling via inhibition of smooth muscle cell migration. Respir Res 2005;6:128.
116. Schermuly RT, Kreisselmeier KP, Ghofrani HA, Samidurai A, Pullamsetti S, Weissmann N, et al. Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension. Circ Res 2004;94:1101-8.
117. Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol 2002;24:159-84.
118. Ghofrani HA, Rose F, Schermuly RT, Olschewski H, Wiedemann R, Weissmann N, et al. Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension. Am Crit Care Med 2002;30:2489-92.
119. Boswell-Smith V, Spina D, Oxford AW, Comer MB, Seeds EA, Page CP. The pharmacology of two novel long-acting phosphodiesterase 3/4 inhibitors, RPL554 [9, 10-dimethoxy-2(2, 4, 6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3, 4, 6, 7-tetrahydro-2H-pyrimido[6, 1-a]isoquinolin-4-one] and RPL565 [6, 7-dihydro-2-(2, 6-diisopropylphenoxy)-9, 10-dimethoxy-4H-pyrimido [6, 1-a]isoquinolin-4-one]. J Pharmacol Exp Ther 2006;318:840-8.
120. Franciosi LG, Diamant Z, Banner KH, Zuiker R, Morelli N, Kamerling I, et al. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials. Lancet Respir Med 2013;1:714-27.
121. Collins JJ, Elwell MR, Lamb JC, Manus Allan G, Heath James E, Makovec GT. Subchronic toxicity of orally administered (gavage and dosed-feed) theophylline in Fischer 344 rats and B6C3F1 mice. Fundam Appl Toxicol 1988;11:472-84.
122. Nyska A, Herbert RA, Chan PC, Haseman JK, Hailey JR. Theophylline-induced mesenteric periarteritis in F344/N rats. Arch Toxicol Sci 1998;72:731-7.
123. Bishop SP. Animal models of vasculitis. Toxicol Pathol 1989;17:109-17.
124. Ruben Z, Deslex P, Nash G, Redmond NI, Poncet M, Dodd DC. Spontaneous disseminated panarteritis in laboratory beagle dogs in a toxicity study: a possible genetic predilection. Toxicol Pathol 1989;17:145-52.
125. Bian H, Zhang J, Wu P, Varty LA, Jia Y, Mayhood T, et al. Differential type 4 cAMP-specific phosphodiesterase (PDE4) expression and functional sensitivity to PDE4 inhibitors among rats, monkeys and humans. Biochem Pharmacol 2004;68:2229-36.
126. Dietsch GN, DiPalma CR, Eyre RJ, Pham TQ, Poole KM, Pefaur NB, et al. Characterization of the inflammatory response to a highly selective PDE4 inhibitor in the rat and the identification of biomarkers that correlate with toxicity. Toxicol Pathol 2006;34:39-51.
127. Dagues N, Pawlowski V, Sobry C, Hanton G, Borde F, Soler S, et al. Investigation of the molecular mechanisms preceding PDE4-inhibitor-induced vasculopathy in rats: TIMP-1, a potential predictive biomarker. Toxicol Sci 2007;100:238-47.
128. Lehnart SE, Wehrens XHT, Reiken S, Warrier S, Belevych AE, Harvery RD, et al. Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias. Cell 2005;123:25-35.
129. Robichaud A, Stamatiou PB, Jin SL, Lachance N, MacDonald D, Laliberté F, et al. Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J Clin Invest 2002;110:1045-52.
130. Movsesian MA, Alharethi R. Inhibitors of cyclic nucleotide phosphodiesterase PDE3 as adjunct therapy for dilated cardiomyopathy. Expert Opin Investig Drugs 2002;11:1529-36.
131. Dorigo P, Gaion RM, Belluco P, Borea PA, Guerra L, Mosti L et al. Antagonism towards endogenous adenosine and inhibition of cGI-PDE in the cardiac effects of amrinone, milrinone and related analogues. Gen Pharmacol 1992;23:535-41.
132. Masciarelli S, Horner K, Liu C, Park SH, Hinckley M, Hockman S, et al. Cyclic nucleotide phosphodiesterase 3A-deficient mice as a model of female infertility. J Clin Invest 2004;114:196-205.
133. Choi YH, Park S, Hockman S, Zmuda-Trzebiatowska E, Svennelid F, Haluzik M, et al. Alterations in regulation of energy homeostasis in cyclic nucleotide phosphodiesterase 3B-null mice. J Clin Invest 2006;116:3240-51.
134. Kerfant BG, Zhao D, Lorenzen-Schmidt I, Wilson LS, Cai S, Chen SR, et al. PI3K is required for PDE4, not PDE3, activity in subcellular microdomains containing the sarcoplasmic reticular calcium ATPase in cardiomyocytes. Cir Res 2007;101:400-8.